NIMG-93. DISCRIMINATION OF CLINICALLY IMPACTFUL TREATMENT RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING BEVACIZUMAB TREATMENT

INTRODUCTION: Clinicians have few effective tools for assessing treatment response in glioblastoma that are predictive of patient outcomes. In previous work, a personalized response metric based on a proliferation-invasion tumor mathematical model, Days Gained, was prognostic for progression-free an...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Singleton, Kyle W, Johnston, Sandra K, Hawkins-Daarud, Andrea, Rickertsen, Cassandra R, De Leon, Gustavo, Kunkel, Lauren, Whitmire, Scott A, Clark-Swanson, Kamala, Bendok, Bernard, Mrugala, Maciej, Porter, Alyx, Swanson, Kristin R
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692666/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.662
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares